

INDEX

A

- Abundant neutral losses..... 43
- Acidic phospholipids 216
- Adenine nucleotide transporter 4
- Adipose tissue
- genomic DNA analysis
 - cells preparation and suspension 348–349
 - GC/MS analysis 350–351
 - hydrolysis 349–350
 - preparation 349
 - purine dR derivatization 350–351
 - standards 349
 - ²H₂O labeling
 - adipose tissue TG 353
 - body water analysis 342, 344, 351–352
 - cell division measurement 340–341
 - de novo lipogenesis (DNL)..... 339–340
 - deuterated water labeling, animals 344
 - fatty acids and glycerol..... 342, 343
 - fractional cell proliferation rate..... 356
 - fractional DNL..... 353
 - fractional synthesis rate (FSR)..... 352–353
 - genomic DNA analysis 342, 343
 - growing obese rats application 345
 - isotope methodologies 338
 - lipid analyses 341, 343
 - lipid synthesis rate 353–356
 - thin-layer chromatography 341–342
 - total lipid extraction..... 341–343
 - lipid analyses
 - fatty acids and glycerol..... 347
 - glycerol GC/MS analysis..... 348
 - glycerol separation and derivatization 347
 - lipid classes separation, TLC 346–347
 - palmitate GC/MS analysis 347–348
 - total lipid extraction..... 345–346
 - lipolytic proteome mapping
 - activity tagging..... 501, 503
 - equipment..... 500–501
 - fractionation 501
 - gel electrophoresis..... 501–505
 - homogenization 502–503
 - LC–MS/MS analysis..... 502, 507
 - lipolytic proteome..... 507–508
 - phosphonate activity-based probes 499–500
 - proteolytic in-gel digestion 502, 505–507
 - specific tagging 498
 - tryptic peptides 507, 509
 - visualization 502, 505
 - metabolic pathways..... 71
 - TG synthesis measurement 338–339
 - tissue and body water collection 344
- Ageing erythrocytes..... 130
- Age-related macular eye disease (AMD)..... 247, 250
- Albumin..... 71
- O-Alk-1 -enyl aliphatic chain..... 289
- Alzheimer's disease..... 289
- Ammonium hydroxide 44
- Anionic glycerophospholipids 25, 26
- Anion, of stearic acid..... 117
- Antibody-based assays..... 73
- Apolipoprotein 71
- Apolipoprotein A1 82
- AQUA peptide 79
- Arabinogalactan..... 90, 95
- Arachidonic acid..... 33, 73, 271
- Atherosclerosis 104
- Atmospheric pressure chemical ionization
(APCI)..... 104, 162, 202, 223
- Atmospheric pressure chemical ionization mass
spectrometry (APCI/MS)..... 166
- Atmospheric pressure photo ionization
(APPI)..... 166–167, 223
- Automatic gain control (AGC) 253

B

- Behenyl oleate (BO)..... 226, 229
- BHT, for protecting lipids from oxidation..... 83
- Bioactive lipids 73
- Bioactive sphingolipids (SPLs) quantitative analysis
- ceramide 1-phosphates (Cer-1P)..... 460–461
 - collision energy and retention times 458–464
 - data presentation..... 445–456
- ESI/MS
- multiple reaction monitoring 451–453
 - precursor ion scan (PI)..... 450–451
 - scan modes..... 450
 - glucosyl/galactosyl-ceramides (Glu-Cers) 462–433
- HPLC conditions..... 456–458
- identification..... 453
- lactosylceramide (Lac-Cer)..... 463
- mass spectrometry approach..... 445–446

- Bioactive sphingolipids (SPLs) quantitative analysis
(Continued)
- materials
 - analytical standards 447
 - equipment 446
 - reagents 446–447
 - supplies 448
 - quantitation
 - calibration curve slopes 453–455
 - internal standards selection 454–455
 - sample preparation and extraction 448–450
 - sphingomyelins (SMs) 463–464
 - sphingosine 446, 456
 - sphingosine 1-phosphate 446, 457
 - structural diversity and nomenclature 444–445
 - Biological tissues lipids, types 212
 - Biomimetic models. *See also* Membrane lipidomics
 - and unsaturated fatty acids geometry
 - fatty acid isomerization 401–402
 - liposomes, biomimetic chemistry membrane models
 - bilayer arrangement 396
 - free radical processes 395
 - heterogeneous system reactivity 396–397
 - isomerization 398
 - multilayer vesicles (MLV) 396
 - 2,3-Bisphosphoglycerate mutase deficiency 131
 - BLAST, for peptides to confirm structure 79
 - Body water analysis
 - acetone extraction and transfer 352
 - body water distillation 351
 - GC/MS analysis, acetone 352
 - Brain mitochondrial isolation 5–7
 - Brain mitochondrial lipidome 17
 - Bronchoalveolar lavage fluid (BALF) 163
 - Bruch's membrane 248
 - Butylated hydroxy-toluene (BHT) 139, 175
- C**
- Calcium homeostasis 3
 - Cancer 20, 162
 - Cardiolipin 4, 17, 21, 152
 - Cardiovascular disease 20, 162
 - Carnitine acyltransferase 4
 - Cationic lipids 190
 - Caveolae
 - cell labeling of lauridan 266, 268
 - GC analysis, fatty acid methyl esters 265–267
 - GP-value calculation 268
 - isolation
 - procedure from cultured cells 262
 - solutions preparation 263–265
 - visualization
 - of lipid rafts using 266
 - RGB images, of lauridan-labeled CD4⁺ T cells 269
 - Cell lipidome, with ¹³C isotope 92
 - Cell membrane structure, alteration of 261
 - Ceramide 1-phosphates (Cer-1P) 460–461
 - Ceramides 35, 39, 67, 74, 133, 222, 227, 229
 - Cerebrospinal fluids (CSF)
 - apolipoprotein A1, peptidomass digest of 82
 - lipid-metabolizing proteins
 - liquid chromatography, of peptides 77
 - mass spectrometry, of peptides 77
 - quantification of 77–79
 - Shotgun-sequencing of 76
 - from UniProt Knowledgebase 80–81
 - lipids
 - detection and analyses of 75–76
 - extraction of 75
 - Charged aerosol detection, HPLC
 - analysis 475–476
 - approaches comparison 470–472
 - corona CAD parameters 474
 - fat-soluble vitamins 478–482
 - fatty alcohols 478–479
 - free fatty acids 476–478
 - HPLC system parameters 473–474
 - materials
 - equipment 472
 - HPLC mobile phases 473
 - reagents and supplies 472
 - reversed-phase-CAD approach 472
 - sample preparations 474–475
 - Chip-based nano-electrospray ionization (nESI) 37
 - Chl esters 222
 - Chloride (Cl⁻) ion 42
 - Cholera toxin b immunostaining 9
 - Cholesterol (Chl) 222
 - Cholesteryl esters 35
 - Cholesteryl oleate 227
 - Chronic obstructive pulmonary disease (COPD) 162
 - Collision energies 43
 - Collision energy and retention times 458–464
 - Collision-induced dissociation (CID) 21, 55, 76, 141, 142, 145, 150, 157, 169, 273, 413–414
 - Colonocyte 262
 - Complementary precursor
 - ion scan 35, 47, 48, 54, 57, 61.
 - See also* Neutral loss scans mode analysis
 - Confocal Raman microscopy
 - advantages and disadvantages 521–522
 - band assignments 519–520
 - biochemical constituents 528, 530
 - calibration 523–524
 - chemical structures 517–518, 529
 - discrimination power 518–519
 - lipids and lipid-soluble compounds 516–517

- localisation and distribution of molecules..... 513–514
- materials
- equipment..... 522–523
 - reagents and supplies 523
- membrane lipids 514–515
- multivariate statistics 522
- physical interactions..... 529
- pulmonary surfactant 515
- qualitative mapping 525–528
- quantitative mapping 529
- validation 524–525
- vitamin E..... 515–516
- Contaminants
- to avoid 139, 217
 - in LC/MS chromatograms 215
- Corona CAD parameters 474
- Creatine kinase 4
- Cyclooxygenase (COX) 73, 162, 271
- Cysteinyl-containing leukotrienes 168
- Cytochrome P450 (CYP)..... 162
- D**
- 7-Dehydrocholesterol..... 140
- De novo lipogenesis (DNL) 339–340
- Depression..... 20
- Design peptides, in silico using Peptidmass 79
- DHA-containing glycerophospholipids 19, 20, 29
- quantification, mass spectrometer scan 27–28
 - structural characterization 27
- Diabetes mellitus (DM) 164
- Diacylglycerols..... 103, 132
- Di- and triesters 222
- Dietary fat
- composition on membrane structure, impact of..... 261
 - to measure biomarkers for 210
- Dietary lipid, changes in..... 72
- Dihomo- γ linoleic (20:3, n-6) (DHGLA)..... 271
- 2,5-Dihydroxybenzoic acid (DHB)..... 106, 108, 253
- Dihydroxyicosatetraenoic acids (DHETEs) 168
- Diisopropyl-amine (DIPA) 137
- 2-Dimensional liquid chromatography..... 84
- Dimethyl sulfoxide (DMSO) 93
- 1,2-Dimyristoyl-phosphatidylethanolamine..... 239
- 2D ion trap 168
- 3D ion trap 168
- Dipalmitin..... 227
- 1,2-Distearoyl-phosphatidylserine (SPPS)..... 239, 240
- 2,6-Di-tert-butyl-p-cresol..... 139
- DNL. *See* De novo lipogenesis (DNL)
- 2D NMR spectroscopy..... 91
- Docosahexaenoic acid (DHA22:6 n-3) 19, 33, 34
- Down syndrome 289
- Dry eye disease 247
- 2D-TLC systems..... 90
- E**
- EDTA-containing samples..... 135
- EFA profiling, of RBC membrane 128
- Eicosanoids..... 73, 161, 162, 271
- analysis of 163
 - biosynthesis 161
 - chromatographic separation of 179
 - ESI/MS/MS chromatogram 180
 - MS² analysis, of 5-HETE and 12-HETE 181
 - quantitation of 171–174
 - selective reaction monitoring of..... 171
- Eicosapentaenoic (20:5, n-3) (EPA) acids 19–22, 271
- Electron capture (EC) 166
- Electron capture dissociation (ECD) 169
- Electron transport chain..... 4
- Electrospray ionization (ESI) 34, 104, 162, 165–166, 202, 223, 272
- Electrospray ionization HPLC/ ESI-MS 90
- Electrospray ionization/mass spectrometry (ESI/MS)
- multiple reaction monitoring..... 451–453
 - precursor ion scan (PI)..... 450–451
 - scan modes..... 450
- Electrospray-ionization mass spectrometry (ESI-MS) 20
- ELISA, for detection of enzyme expression 73
- Enzyme-immunoassay techniques (EIA) 162, 272
- EPO-receptor signaling system 131
- Epoxyeicosatrienoic acids (EETs) 161
- Epoxygenases..... 73
- Equipment
- for lipidomics..... 73
 - for proteomics..... 74
- Ergosterol 140
- Essential fatty acid (EFA) 127
- F**
- Fat-soluble vitamins, HPLC-charged aerosol
- detection 478–482
- Fatty acid (FA) 21, 73
- amides..... 222
 - molar ratios..... 128
- Fatty acid elongases
- cultured cells assessment
 - extraction and analysis, metabolites 382
 - high performance liquid chromatography..... 383–384
 - primary hepatocytes..... 381–382
 - saponification..... 382–383
- in vivo* assessment
- adenoviral-mediated over expression 384
 - loss-of-and gain-of-function 384

- Fatty acid elongases (*Continued*)
 primary hepatocytes infection..... 384–385
 recombinant adenovirus generation
 methods 384–385
 recombinant adenovirus infection..... 385–386
 microsomes
 control studies..... 380–381
 enzymatic assay..... 380
 extraction and analysis 380
 preparation..... 379
Fatty acid methyl esters (FAMES)..... 488
Fatty acid profiles and TAGs determination,
 MALDI-TOF/MS fingerprinting
 conventional methods..... 321–324
 determination methods..... 317
 GC/MS determination comparison 332–333
 materials
 equipments 317
 reagents..... 317–318
 olive oils..... 319–321
 composition 320
 fingerprinting..... 320–321, 324
 oil extraction 319–320
 quantitative information 319–320, 322
 pomegranate and soybean oil..... 325–327
 MALDI analysis..... 325, 327
 plant material and extraction 325
 TAG profiling..... 325–326
 theoretical molecular mass 319
 vegetable oils..... 318–319, 327–332
Fatty acid profiles, vegetable oils
 allowable fatty acid ranges 328
 GC/MS determination..... 329
 linolenic acid isomers..... 331
 oil quality..... 327–329
 pomegranate oils..... 329–332
Fatty alcohols, HPLC-charged
 aerosol detection 478–479
Ficoll and sucrose gradients..... 4
Ficoll gradient 16
Fluorescence resonance energy transfer
 (FRET)..... 268
Fluorescent suicide inhibitors, lipolytic proteome mapping
 activity tagging 503
 gel electrophoresis..... 503–505
 homogenization..... 502–503
 LC-MS/MS analysis..... 502, 507
 lipolytic proteome..... 507–508
 materials
 activity tagging..... 501
 equipment..... 500–501
 fractionation 501
 gel electrophoresis..... 501–502
 proteolytic in-gel digestion 502
 phosphonate activity-based probes 499–500
 proteolytic in-gel digestion 505–507
 specific tagging 498
 tryptic peptides..... 507, 509
 visualization 502, 505
Fourier transform ion cyclotron resonance mass
 spectrometry (FT-ICR MS) 90, 169–171
Fractional synthesis rate (FSR)..... 352–353
Free cholesterol..... 227, 229
Free fatty acids..... 222
Free fatty acids HPLC-charged aerosol
 detection 476–478
FSR. *See* Fractional synthesis rate
FTICR/MS instrument 170
Full width at half-height maximum (FWHM) 165
- G**
- Gangliosides 216
Gas chromatography (GC)..... 34
Gas chromatography coupled to mass spectrometry
 (GC/MS)..... 162
Gas chromatography separation, *cis* and *trans*
 isomers..... 405, 408
Gas-liquid chromatography (GLC)..... 128, 367–368
Gel electrophoresis
 1D gel electrophoresis 503–504
 2D gel electrophoresis 504–505
Genomic DNA analysis, adipose tissue
 cells preparation and suspension..... 348–349
 GC/MS analysis 350–351
 hydrolysis..... 349–350
 preparation..... 349
 purine dR derivatization..... 350–351
 standards..... 349
GLC. *See* Gas-liquid chromatography (GLC)
Glial cell bodies 3
Global ¹³C-enrichment strategy..... 92
Glucosyl/galactosyl-ceramides (Glu-Cers)..... 462–433
Glutamate metabolism 3
Glycerophosphatidic acid (GPA) 35, 67
Glycerophosphatidylcholine (GPCho)..... 35, 39, 42–48
Glycerophosphatidylglycerol (GPGro)..... 35, 67
Glycerophosphatidylinositol..... 35
Glycerophosphatidylserine (GPSer)..... 35, 54–59
Glycerophospholipids (GPLs)..... 16, 19, 20, 28, 37
 containing DHA, in mouse skeletal muscle..... 29
 distribution of DHA, workflow for tracking 23
G-protein-coupled receptors 288
- H**
- Haematopoietic stem cells..... 130
Hemoglobinopathies 133
n-Hexane-propan-2-ol solvent..... 244
High performance liquid chromatography (HPLC)
 charged aerosol detection
 analysis..... 475–476
 approaches comparison..... 470–472

- corona CAD parameters..... 474
- fat-soluble vitamins..... 478–482
- fatty alcohols..... 478–479
- free fatty acids..... 476–478
- HPLC system parameters..... 473–474
- materials..... 472–473
- reversed-phase-CAD approach..... 472
- sample preparations..... 474–475
- disadvantage..... 104
- eicosanoids quantification..... 162
- meibum..... 222
- phospholipids..... 289
- solvents..... 74, 75, 223, 244, 275, 279, 280
- High-performance liquid chromatography–tandem mass spectrometry (HPLC–MS)..... 458–464
- High-pressure liquid chromatography–mass spectrometry (HPLC–MS)..... 221
- ²H₂O labeling, adipose tissue development
 - adipose tissue TG..... 353
 - body water analysis..... 342, 344, 351–352
 - cell division measurement..... 340–341
 - De novo lipogenesis (DNL)..... 339–340
 - deuterated water labeling, animals..... 344
 - fatty acids and glycerol..... 342, 343
 - fractional cell proliferation rate..... 356
 - fractional DNL..... 353
 - fractional synthesis rate (FSR)..... 352–353
 - genomic DNA analysis..... 342, 343
 - growing obese rats application..... 345
 - isotope methodologies..... 338
 - lipid analyses..... 341, 343
 - lipid synthesis rate..... 353–356
 - thin-layer chromatography..... 341–342
 - total lipid extraction..... 341–343
- HPLC–MS. *See* High-performance liquid chromatography–tandem mass spectrometry (HPLC–MS)
- HPLC–MSⁿ procedures..... 243
- Human erythrocytes
 - lipidomic analysis of..... 134–135
 - blood sample collection..... 135–136
 - erythrocyte storage..... 135–136
 - lipid extraction..... 136–139
 - lipid extracts, storage of..... 139–140
 - RBC phospholipids analysis
 - HPLC separation..... 154
 - by tandem hybrid MS/MS (*see* Tandem hybrid MS/MS)
 - by tandem MS2..... 141–145
- Human meibum, analysis..... 225
 - chromatogram, of human meibum sample..... 231
 - extracted chromatogram, of ion *m/z*369..... 232
 - fragmentation patterns, of ions..... 238
 - HPLC gradient, for polar lipid analysis on..... 239
 - HPLC–MS analyses
 - of equimolar mixture, of Chl-O and Chl..... 233
 - nonpolar lipids, structural elucidation
 - of..... 234, 235, 237
 - of nonpolar lipid standard..... 227, 229
 - mass spectra of mixture, of standard lipids and..... 230
 - nonpolar lipid analyses..... 226
 - HPLC procedures..... 226
 - mass spectrometric procedures..... 226–227
 - polar lipid analysis, using gradient NP HPLC–APCI MS
 - chromatogram, of mixture of polar lipids..... 240
 - HPLC procedures..... 238–239
 - mass spectrometric procedures..... 239
 - reconstructed chromatograms, of polar lipids..... 241, 243
 - sample collection..... 225
 - structural elucidation, of meibum compound
 - m/z* 619..... 236
 - total ion chromatogram..... 228
- Human red blood cell (RBC) membrane..... 127
- Hybrid analyzers..... 171
- Hydrocarbons..... 222
- Hydroxyeicosatetraenoic acids (HETEs)..... 161
- 12-Hydroxyheptadecatrienoic acid (12-HHT)..... 168
- I**
 - Imaging mass spectrometry (IMS)..... 248
 - for analyzing flat-mounted eye segments..... 252
 - averaged MS/MS spectrum, of *m/z* 782.6..... 258
 - fixation conditions, verification of..... 254
 - fundus and macula, images captured by..... 257
 - image processing, and interpretation..... 255–256
 - lipid identification..... 256
 - mounting tissue for..... 252
 - Immunoelectron microscopy..... 268
 - Infrared multiphoton dissociation (IRMPD)..... 169
 - Infrared spectroscopy..... 222
 - In situ* corona discharge..... 416, 418–419
 - Ion trap mass analyzers..... 167–169, 223
 - Isomeric phospholipids..... 29
 - Isotope corrections..... 30
- J**
 - JAK2 mutations..... 131
- L**
 - Lactosylceramide (Lac-Cer)..... 463
 - Large unilamellar vesicles by extrusion technique (LUVET)..... 398–400, 403–405
 - cis*–*trans* isomerization regioselectivity..... 398–399
 - irradiation conditions, isomerization..... 404–405
 - preparation..... 403–404
 - Laurdan..... 266
 - Laurdan-labeled CD4⁺ T cells..... 269

- LC/MS/MS-based quantification method,
for eicosanoid..... 163
- LCQ ion trap mass spectrometer 77
- Lecithin-cholesterol acyl transferase 128
- Less polar nonwater-soluble solvent..... 137–138
- Leukotrienes (LTs) 161
- Limit of detection (LOD) 164
- Lipases..... 72, 73
- Lipid analyses
fatty acids..... 347
fatty acids and glycerol separation and
derivatization 347
glycerol 347
glycerol GC/MS analysis..... 348
lipid classes separation, TLC 346–347
palmitate GC/MS analysis 347–348
total lipid extraction..... 345–346
- Lipid composition
altering during thawing 217
of human TF and TFLL..... 222
- Lipid extraction
for determining phosphoinositides, PtdIns, PIP,
and PIP2..... 190
and fractionation..... 193
from rat retinal tissue..... 36–37
requiring ratio of chloroform, methanol,
and water 217
SCX column for 192
solvent preparation for..... 191
- Lipid maps database 83
- Lipid mass spectrum analysis (LIMSA) 37, 129
- Lipid metabolic pathways..... 71
disruption of 66
- Lipid metabolizing proteins, changes in..... 72
- Lipid modification..... 72
- Lipidomic analysis 202
approach, lipids from 208
to investigate
lipid composition effects 203
lipid metabolism role 203
- large lipids analysis 212–213
by LC/MS 213
by MS/MS..... 214
by LC–ESIMS/MS..... 291–292
- LC/MS analysis
of lipids..... 210–212
maintenance and system suitability
testing 215–216
prostanoids assay..... 273
reagents for 74
sample preparation, for analysis 207
biological fluids..... 209–210
cells 207
tissues..... 208–209
- small lipids analysis..... 210–212
by LC/MS 211
- sterol lipids analysis 212–213
- to study
abiotic environmental factors 202
genetic diversity effects 202–203
lipid metabolism in role 203
nutrients effect..... 202
of patient erythrocyte membranes 129
pharmacological treatments effects 202
- to understand
biochemical mechanisms for..... 203
physiological roles by endogenous lipids in..... 203
- Lipid particles analysis, yeast
cell fractionation SDS–PAGE analysis 364, 369
extraction and quantification 360
fatty acids GLC analysis..... 367–368
isolation 361–362
lipid extraction 363–365
mass spectrometric analysis 370
material
equipment and supplies 360–361
reagents..... 361
- neutral lipids and phospholipids
mass spectrometry..... 369
TLC separation 370–372
- phospholipids TLC analysis 366–367
protein analysis 363, 364
sterols GLC analysis..... 368
- Lipids
biological roles 201–202
chemical classification of 205
rafts..... 268
- Lipids non-invasive mapping. *See also* Magnetic
resonance imaging
calibration procedure 490–492
data acquisition..... 489–490
grains and rapeseed..... 486
living barley grain quantitative imaging..... 492–493
materials
equipment..... 487–488
reagents..... 488
sample preparation and processing 488
small-sized rape seed 494–495
total esterified fatty acids 488
- Lipolytic proteome mapping, adipose tissue
activity tagging 501, 503
equipment..... 500–501
fractionation 501
gel electrophoresis..... 501–505
homogenization..... 502–503
LC–MS/MS analysis..... 502, 507
lipolytic proteome 507–508
phosphonate activity-based probes 499–500

- protein patterns..... 507
 proteolytic in-gel digestion502, 505–507
 specific tagging 498
 tryptic peptides 507, 509
 visualization 502, 505
- Lipoprotein lipase..... 128
- Lipoxins (LXs) 162
- Lipoxygenase (LOX) 73, 162
- Liquid chromatography electrospray ionization
 mass spectrometry (LC–ESIMS) 288
- Liquid chromatography–tandem mass spectrometry
 (LC–MS/MS) 162, 272
- Long chain polyunsaturated fatty acids
 (LCPUFA) 33, 34
- LTQ database of CSF peptides 79
- LUVET. *See* Large unilamellar vesicles by extrusion
 technique (LUVET)
- LysoPC (LPC) 289
- Lysophosphatidic acid (LPA) 288
- Lyso-phosphatidylcholine 107
- Lysophosphatidylcholine acyltransferase (LPCAT) 134
- Lysophosphatidylcholines (LPCs) 104, 190
- Lysophosphatidylserine (LPS) 288
- Lysophospholipids 73
- M**
- Magnetic resonance imaging
 advantages and disadvantages 486–487
 calibration procedure 490–492
 data acquisition 489–490
 grains and rapeseed 486
 living barley grain quantitative imaging 492–493
 materials
 equipment 487–488
 reagents 488
 sample preparation and processing 488
 small-sized rape seed 494–495
 total esterified fatty acids 488
- MALDI-TOF. *See* Matrix-assisted laser desorption/
 ionization time-of-flight
- MALDI-TOF MS. *See* Matrix-assisted laser desorption
 and ionization time-of-flight mass spectrometry
- Mammalian fatty acid elongases
 cultured cells assessment
 extraction and analysis, metabolites 382
 high performance liquid chromatography
 383–384
 primary hepatocytes 381–382
 saponification 382–383
 hepatic microsomal reaction sequence 375–377
in vivo assessment
 adenoviral-mediated over expression 384
 loss-of-and gain-of-function 384
 primary hepatocytes infection 384–385
- recombinant adenovirus generation
 methods 384–385
 recombinant adenovirus infection 385–386
- materials
 equipment 378
 reagents and supplies 378–379
- microsomes
 control studies 380–381
 enzymatic assay 380
 extraction and analysis 380
 preparation 379
 pathway 376
- Marker antibodies, lipid particles 363–364
- Mass spectrometry (MS) 104, 222
 instrumentation 8–9, 25
 with or without HPLC 222
 phospholipids containing DHA,
 identification 25–27
 process for thin brain tissue section by 249
 sample preparation 8
 techniques, for eicosanoid HPLC/MS/MS
 analysis 164–165
- Mass spectrum
 of crude rat retina lipid extract 38–39
 of erythrocyte PE and PC 145
 of phosphatidylcholines and sphingomyelins 147
 of phosphatidylethanolamine species 146
 for unfractionated rat retina lipid extract 38
- Matrix-assisted laser desorption and ionization
 time-of-flight mass spectrometry 104–107
 brain phosphoinositides, analysis by 189
- MALDI-TOF mass spectra
 of lipid extract 120
 of organic bovine liver extract 115
 of 1-palmitoyl-2-oleoyl-*sn*-phosphatidylcholine
 and 113
 quantitative data analysis 111–112
 recording of 110–111
 positive ions, detected of liver extract and 116–117
 sample processing
 artificial lipid samples 108–109
 crude lipid, separation of 109–110
 liver extract, preparation 109
- Matrix assisted laser desorption/ionization
 (MALDI) 34, 258
- Matrix-assisted laser desorption/ionization mass
 spectrometry (MALDI–MS) 248
- Matrix-assisted laser desorption/ionization time-of-flight
 conventional methods 321–324
 determination methods 317
 GC/MS determination comparison 332–333
- materials
 equipments 317
 reagents 317–318
 olive oils 319–321

- Matrix-assisted laser desorption/ionization time-of-flight
(Continued)
composition 320
fingerprinting.....320–321, 324
oil extraction 319–320
quantitative information319–320, 322
pomegranate and soybean oil..... 325–327
MALDI analysis..... 325, 327
plant material and extraction 325
TAG profiling..... 325–326
theoretical molecular mass 319
vegetable oils.....318–319, 327–332
- Meibomian glands (MG) 221
- Membrane fluidity..... 4
- Membrane lipidomics and unsaturated fatty acids geometry
cell membrane isolation, cultures 406–407
flame ionization detector (FID)..... 403
gas chromatography separation..... 405, 408
isomerization, cell membranes 401–402
liposomes, biomimetic chemistry membrane models
bilayer arrangement 396
free radical processes 395
heterogeneous system reactivity 396–397
isomerization 398
multilayer vesicles (MLV) 396
- LUVET
cis-trans isomerization regioselectivity 398–399
irradiation conditions, isomerization 404–405
preparation..... 403–404
- materials
equipments 402–403
reagents and supplies 403
photolysis reactor..... 402
radical-catalysed *cis-trans* isomerization 393
reactive positions 392–393
tandem protein–lipid damage 399–400
TLC, argentation technique 406
- trans* isomer detection
analytical methods 394
membrane compartment..... 395
trans lipids 394–395
- unilamellar vesicles
injection methodology preparation 404
micrography..... 407–408
- Membrane lipids 514–515
functions 514–515
lipids and lipid-soluble compounds 516–517
localisation and distribution..... 513–514
materials
equipment..... 522–523
reagents and supplies 523
- Membrane proteins 20
- Membrane rafts 261
- Methylcarbonate (CH₃OCO₂⁻) anions 34, 46
- Microsomes. *See also* Mammalian fatty acid elongases
control studies..... 380–381
enzymatic assay..... 380
extraction and analysis 380
preparation..... 379
- Mitochondria
DNA..... 3
lipid composition 10
of C57BL/6J mouse brain 11
purification 7
NS mitochondria 7
Syn mitochondria 7–8
purity 9
protein markers, on Western blots 10
mass content, of lipids
of anionic lipids 11–13
of weak anionic lipids 14
weak polar lipids 15–16
- Mitochondrial lipidome 3
- Mitochondrial membrane lipids 4
- Mono acyl glycerols 35, 222
- 1-Monomyristoyl glycerol 227
- MS/MS conditions..... 37
- MS/MS scan mode 35
- MSⁿ analyses..... 223
- Multiple reaction monitoring (MRM) 78, 79, 273, 288
- Murine brains 191
lipid extract fractions
mass spectra of..... 196
negative ion mode mass spectra 197
- Mycobacterial lipidome 90
- Mycobacterial lipid profiling 91
cell culture and preparation..... 92–93
extraction methods 96
- M. bovis* BCG, HSQC spectrum
2D HSQC lipid profile 97
2D-HSQC mycolic acid profile..... 99
polar and apolar lipid profiles 100
mycolic acid pool, preparation 95
to probe gene function..... 98
total free lipid pool, extraction and analysis 93–95
- Mycobacterium tuberculosis* 90
- Myelin membranes 4
- N**
- Nano-electrospray ionization (nESI)..... 37, 38
- N*-Cyclohexyl-*N'*-dodecanoic acid urea
(CUDA) 172
- Nephritis..... 162
- nESI-MS..... 37
- Neutral lipids and phospholipids
mass spectrometry 369
TLC separation 370–372
- Neutral loss scan (NLS) 43, 44

- Neutral loss scans mode analysis
for class-specific identification
of lipid molecular species 40–41
for global lipid analysis 39
of rat retina DG and TG lipids 59, 61, 62
of rat retina GPEtn and GPIns lipids 48, 52, 54
of rat retina GPser lipids 54–59
of rat retina SM and GPcho lipids 39
negative ion analysis 39, 42–44
positive ion analysis 44–48
- Neutral scanning, for PE 289
- Nitrocellulose 259
- Nitrogen 136
- NMR software 91
- NMR spectroscopy 90, 91
- Nonpolar lipids 222
- Nonpolar nonwater-soluble solvents 137
- Nonsynaptic (NS) mitochondria 3
- Normal phase HPLC (NP HPLC) 223
- Nuclear magnetic resonance spectrometry 222
- O**
- Obesity 20
- Octadecyl (C18) acyl chains 137
- Oleamide 215, 227
- Olive oils, TAG profiling
composition 320
fingerprinting 320–321, 324
oil extraction 319–320
quantitative information 319–320, 322
- Omega-3 fatty acids 19, 262
- Online ozonolysis methods, double bond position
determination
anionic ether phospholipid, human lens 438
collision induced dissociation (CID) 413–414
- OzESI-MS
ESI-MS spectrum, GPA 428–429
external ozone generation 416, 419–421
GPcho isomeric standards 429–431
human lens extract 431–433
ion source modification 420–421
neutral losses/gains 430–431
performance 421–422
in situ corona discharge 416, 418–419
total ion current (TIC) 429
- OzID 416–417
GPcho isomeric standards 433–434
instrument modification 426
ion trap and setting 424–425
PEEKsil restriction 423–424
positive and negative ion examples 434–437
preparation 422–423
trimethylamine neutral loss 426
position difference 414
- precursor lipid ion *vs.* ozonolysis product
ion 438–439
reagents and supplies 417–418
safety precautions 426–428
- Optic nerve head (ONH) 255
- Oxo-fatty acids 161
- 5-Oxo-7-glutathionyl-8,11,14-eicosatrienoic acid
(FOG₇) 168
- Oxylipin stereoisomers, analysis of 164
- OzESI-MS. *See* Ozone electrospray ionization–mass spectrometry (OzESI-MS)
- OzID. *See* Ozone-induced dissociation (OzID)
- Ozone electrospray ionization–mass spectrometry (OzESI-MS)
ESI-MS spectrum, GPA 428–429
external ozone generation 416, 419–421
GPcho isomeric standards 429–431
human lens extract 431–433
ion source modification 420–421
neutral losses/gains 430–431
performance 421–422
in situ corona discharge 416, 418–419
total ion current (TIC) 429
- Ozone-induced dissociation (OzID) 27
GPcho isomeric standards 433–434
instrument modification 426
ion trap and setting 424–425
PEEKsil restriction 423–424
positive and negative ion examples 434–437
preparation 422–423
trimethylamine neutral loss 426
- P**
- 1-Palmitoyl-2-oleoylphosphatidic acid
(POPA) 239, 240
- 1-Palmitoyl-2-oleoyl-phosphatidylcholine
(POPC) 239, 240, 242
- 1-Palmitoyl-2-oleoyl-phosphatidylglycerol
(POPG) 239, 240, 242
- Para*-nitroaniline (PNA) 106
- Peak-area ratio 282
- PE-plasmalogens, detection
using RPLC-ESIMS/MS 289
data-dependent scanning 292
detection, of PA and PS 297
2D-map of phospholipids 293
identification of phospholipids 292
mass spectrometry conditions 292
molecular species of PC mixture,
identified by 295
MS/MS spectra of [M + HCO₂]⁻ ions of
PCs from 294
search engine, for Identification of 296–297
by ultra performance LC (UPLC)

- PE-plasmalogens, detection (*Continued*)
 diacyl- and 1-*O*-alk-1-enyl-2-acyl-PE,
 identification of..... 307
 HPLC and UPLC mobile phases..... 303
 LC separation experiment..... 303–304
 mass spectrometry, conditions..... 304
 molecular species of PE identified..... 308–310
 MS/MS analysis..... 304–306
 quantitative analysis..... 306, 311
 sample procedure..... 303
 specific detection of..... 306
- Peptidoglycan..... 90
- Peroxisomal enzyme..... 128
- PGO. *See* Pomegranate oil
- Phagocytosis..... 130
- Pharmacologic assays..... 73
- Phenolicglycolipid (PGL)..... 97
- Phosphatidylcholine (PCho)..... 250, 255, 256
- Phosphatidic acid..... 21, 103, 288
- Phosphatidylcholines..... 20, 118, 128, 129, 133, 289
- Phosphatidylethanolamine (PE)-plasmalogens..... 288
- Phosphatidylethanolamines..... 20, 118, 128–130
 contour plot of..... 153
 separation of..... 155–156
- Phosphatidylglycerol..... 21, 67, 112, 289
- Phosphatidylinositol..... 21, 35, 118, 128, 129,
 132, 190, 192–195, 289
 calibration curves..... 198
- Phosphatidylinositol-4,5-bisphosphate (PIP₂)..... 190
- Phosphatidylinositols..... 128
- Phosphatidylserines..... 21, 74, 118, 128–130, 132,
 141, 152, 288
- Phosphocholine-containing lipids..... 34
- Phosphocholine-derived ions..... 43
- Phosphoinositides..... 103, 216
- Phospholipase A₂..... 72
- Phospholipase C..... 73
- Phospholipase D..... 73
- Phospholipids (PLs)..... 4, 103, 222, 250
- Phospholipids qualitative and quantitative analyses
 approaches..... 287
 LC–ESIMS..... 287–289, 291–269
 lipid molecular species..... 306, 311
 materials
 column..... 290
 reagents..... 290–291
- PE-plasmalogens, LC–ESIMS/MS
 Bligh–Dyer method extraction..... 303
 HPLC and UPLC mobile phases..... 303
 mass spectrometry conditions..... 304
 MS/MS analysis..... 304–306
 specific detection..... 306–310
- phosphatidic acid and phosphatidylserine
 Bligh–Dyer method, extraction..... 298
 butanol extraction..... 298
- DEAE-cellulose column, pretreatment.....
 298–299
 reverse phase LC–ESIMS..... 297
- untargeted and global lipidomics
 data-dependent scanning..... 292
 2D-map..... 292–293
 full-mass scanning..... 292
 HPLC mobile phases..... 292
 LC separation experiment..... 292
 mass spectrometry conditions..... 292
 molecular species..... 295
 MS/MS spectra..... 294
 phospholipids identification, reverse
 phase LC–ESIMS/MS..... 292–293, 295
 survey methods..... 297
- Phosphonate activity-based probes..... 499–500
- Phosphorus assay..... 24–25
- Photodiode array (PDA)..... 168
- Pigmented epithelium (PE)..... 250
- Plasmalogen-deficiency disorders..... 289
- Plasma/RBC contamination..... 135
- Platelet-activating factor..... 73
- Polar water-soluble solvent..... 137
- Polycythemias..... 131
- Polyketides..... 89
- Polysaccharides..... 89
- Polyunsaturated fatty acids (PUFA)..... 83, 139, 271, 272
- Pomegranate and soybean oil, TAG fingerprinting
 MALDI analysis..... 325, 327
 plant material and extraction..... 325
 TAG profiling..... 325–326
- Pomegranate oil (PGO)..... 325–326, 329–330
- POPE, as negative ion..... 114
- POPG, as negative ion..... 114
- Postsource decay (PSD) mass spectra..... 117
- Post-translational modifications (PTMs).....
 of proteins..... 79
- Precursor ion scan (PI)..... 450–451
- Precursor lipid ion *vs.* ozonolysis product ion..... 438–439
- Primary hepatocytes infection..... 385
- Prostacyclins..... 271
- Prostaglandin glyceryl esters..... 167
- Prostaglandins (PGs)..... 161
- Prostanoids
 biological sample
 collection and storage..... 276–277
 preparation..... 274–275
 data analysis..... 282
 HPLC solvents..... 279
 LC/ESI–MS/MS analysis..... 280–281
 sample extraction and LC/ESI–MS/MS
 assay for..... 273
 sample preparation..... 277–278
 sample reconstitution and..... 279
 solid phase extraction..... 275, 278–279

- solutions preparation 274–276
 calibration lines 276
- Prostanoid synthases 272
- Protein kinase C 20
- Proteolytic enzymes 83
- Proteolytic in-gel digestion
 destaining 505–506
 gel fragment preparation 505
 peptide extraction 506–507
 reduction and alkylation 506
 washing 505
- Proteomics
 approaches, in regulating lipid metabolism 73
 reagents for 75
- Proton gradient 4
- Pulmonary surfactant
 alveolar type-II cells 515
 lipids and lipid-soluble compounds 516–517
 localisation and distribution 513–514
 materials
 equipment 522–523
 reagents and supplies 523
- Q**
- Q-Trap analysis
 of diacyl species of phosphatidylethanolamines 149
 of phosphatidylethanolamines extracted from 148
- Quadrupole analyzer 167
- Quadrupole ion trap time of flight (QITTOF) 181
- Quantitative analysis, of LOX products in bovine tissues 168
- Quasimolecular ions 105
- R**
- Radical-catalysed *cis-trans* isomerization 393
- Radio-immunoassay techniques (RIA) 162, 272
- Rat retina, lipid analysis by MS/MS scan mode
 DG and TG molecular species 63–65
 GPEtn species 53
 GPIns species 55
 GPSer molecular species 60
 SM and GPCho molecular species 49–51
- Rat retina sphingomyelin (SM) 35
- RBC membranes
 for medical investigations 129–130
 haematopoiesis and RBC lifetime 130–131
 incorporation of fatty acids into 132–133
 membrane lipids, in hemoglobinopathies 133–134
 phospholipid synthesis, regulation 131–132
 remodeling of phospholipids 133
- RBC phospholipids 128
- Retina 33
 homogenates 36
- Retinal pigment epithelial cells 33
- Retinitis pigmentosa 289
- Reversed-phase-CAD approach 472
- Reverse phase (RP) LC approaches 288
- Reverse phase LC coupled to electrospray
 ionisation (ESI)-MS/MS 272
- Reverse phase LC-ESIMS for lipidomics 303–306
 HPLC mobile phases 299
 LC separation experiment 299
 mass spectrometry conditions 299–300
 molecular species, of PA, PS and lyso-forms
 detected 302
 for PA and PS 297
 phospholipid analysis 300–301
 quantitative analysis 306, 311
 sample pretreatment 298–299
 sample procedure
 Bligh-Dyer method 298
 with butanol 298
- Rheumatoid arthritis 104
- S**
- Saponification, lipids 382–383
- Saturated fatty acids 261
- SCX column 192
- Secondary ion mass spectrometry (SIMS) 249
- Secretory PLA₂ 128
- Selective reaction monitoring (SRM) 162, 288
- Serum lipolytic enzymes 128
- Shotgun lipidomics 4, 29
 analysis of highly purified brain mitochondria by 16
 to evaluate lipid content and 10
 identification of DHA-containing
 glycerophospholipids 20
 for individual lipid species in unfractionated
 lipid extracts 34
 procedure 9
 and quantitation of cellular lipidomes 136
 and tandem MS 4
 using high-throughput platform which 4
- Signal-to-noise ratio 111
- Single ion monitoring (SIM) 231
- Sodium chloride (NaCl) 122
 for dissociation of lipids 122
- Sodium (Na⁺) ions 46
- Solid phase extraction (SPE) 273
- Sphingolipid
 analysis 35
 identification 453
- Sphingomyelins (SM) 35, 118, 129, 140, 141, 289
- Sphingosine 446, 456
- Sphingosine 1-phosphate 446, 457
- Sphingosines 222
- Sterol lipids 212

- Sterols GLC analysis 368
Storage lipids 204
Strong cation exchange (SCX) gel 190
Sucrose gradient 9, 16
Sustained off resonance irradiation (SORI) 169, 170
Synaptic (Syn) mitochondria 3
Synaptic nerve terminal 3
Synaptosomes 7
- T**
- TAG analysis, MALDI-TOF/MS 318–319
Tandem hybrid MS/MS
 RBC phospholipids, analysis of
 CID mode 145
 consequences, of RBC storage on 152
 on enhanced mass resolution mode 145
 ether- and diester subclasses, separation of 152
 ether-, diacyl-, and oxidized RBC PE 155–156
 loss of neutral fragment 145
 phosphatidylethanolamine, mass spectrum
 of 146–147
 Q-Trap analysis of 148
 separation, as function of fatty acid
 composition 154
Tandem mass spectrometry analyses. *See* Neutral loss
 scans mode analysis
Tandem protein–lipid damage 399–400
Tear film (TF) 222
Tear film lipid layer (TFLL) 222
Thiamine pyrophosphate (TPP) 175
Thin-layer chromatography (TLC) 104, 289, 366–367
Thromboxanes (TXs) 161, 271
Time of flight (TOF) 169
TLC. *See* Thin-layer chromatography
Total fatty acid 16
Total ion chromatograms (TIC) 231
Total lipids 22
 extraction 22–24
Total phospholipid concentration 24
Trans fatty acid methyl ester isomers separation 406
Trans isomer detection, unsaturated fatty
 acids geometry
 analytical methods 394
 membrane compartment 395
 trans lipids 394–395
Tri- and di-acylglycerols 59, 132, 222
Trifluoroacetic acid (TFA) 108
Trihydroxyicosatrienoic acids (THETAs) 170
Trimethylamine (TEA) 137
Triolein 227
Triple quadrupole instruments 223
Triple quadrupole mass spectrometer 8, 35, 223
Triple quadrupole (TQ) spectrometer 141
Trypsin 83
- TSQ Quantum Ultra triple quadrupole mass
 spectrometer 37
Two-dimensional ¹H–¹³C heteronuclear single
 quantum coherence (HSQC) NMR 91
Type 2 diabetes 20
- U**
- Ultra performance liquid chromatography
 (UPLC) 162, 303
Unfractionated lipid extracts 34
Unsaturated lipids double bond position determination
 anionic ether phospholipid, human lens 438
 collision induced dissociation (CID) 413–414
OzESI–MS
 ESI–MS spectrum, GPA 428–429
 external ozone generation 416, 419–421
 GPCho isomeric standards 429–431
 human lens extract 431–433
 ion source modification 420–421
 neutral losses/gains 430–431
 performance 421–422
 in situ corona discharge 416, 418–419
 total ion current (TIC) 429
OzID 416–417
 GPCho isomeric standards 433–434
 instrument modification 426
 ion trap and setting 424–425
 PEEKsil restriction 423–424
 positive and negative ion examples 434–437
 preparation 422–423
 trimethylamine neutral loss 426
 position difference 414
 precursor lipid ion *vs.* ozonolysis product
 ion 438–439
 reagents and supplies 417–418
 safety precautions 426–428
UV absorption of olefinic residues 104
UV detector 104
- V**
- Variants of, APOA1_HUMAN 79
Vegetable oils. *See* Fatty acid profiles and TAGs
 determination, MALDI-TOF/MS
 fingerprinting
Vinyl ether 139
Vitamin E, spatial distribution
 biological roles 515–516
 lipids and lipid-soluble compounds 516–517
 localisation and distribution 513–514
 materials
 equipment 522–523
 reagents and supplies 523
Voltage dependent, ion channel 4

W

Warburg theory of cancer.....	17
Wax esters.....	222
Western analysis.....	73
Wet eye disease.....	248

Z

Zellweger syndrome.....	289
Zwitterionic phospholipid.....	30